Xenon Pharmaceuticals Inc (NASDAQ: XENE) established initial surge of 3.19% at $37.17, as the Stock market unbolted on Wednesday, before settling in for the price of $36.02 at the close. Taking a more long-term approach, XENE posted a 52-week range of $33.27-$47.44.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 35.90%. Meanwhile, its Annual Earning per share during the time was -14.28%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -35.02%. This publicly-traded company’s shares outstanding now amounts to $76.42 million, simultaneously with a float of $74.20 million. The organization now has a market capitalization sitting at $2.85 billion. At the time of writing, stock’s 50-day Moving Average stood at $39.10, while the 200-day Moving Average is $40.08.
Xenon Pharmaceuticals Inc (XENE) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Xenon Pharmaceuticals Inc industry. Xenon Pharmaceuticals Inc’s current insider ownership accounts for 3.05%, in contrast to 97.48% institutional ownership. According to the most recent insider trade that took place on Jan 24 ’25, this organization’s PRESIDENT & CEO sold 22,468 shares at the rate of 40.20, making the entire transaction reach 903,214 in total value, affecting insider ownership by 31,302. Preceding that transaction, on Jan 27 ’25, Company’s PRESIDENT & CEO sold 16,315 for 40.50, making the whole transaction’s value amount to 660,806. This particular insider is now the holder of 31,302 in total.
Xenon Pharmaceuticals Inc (XENE) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.99 per share during the current fiscal year.
Xenon Pharmaceuticals Inc’s EPS decrease for this current 12-month fiscal period is -35.02% and is forecasted to reach -4.33 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -9.18% through the next 5 years, which can be compared against the -14.28% growth it accomplished over the previous five years trading on the market.
Xenon Pharmaceuticals Inc (NASDAQ: XENE) Trading Performance Indicators
Let’s observe the current performance indicators for Xenon Pharmaceuticals Inc (XENE). It’s Quick Ratio in the last reported quarter now stands at 17.85. The Stock has managed to achieve an average true range (ATR) of 1.82.
In the same vein, XENE’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.01, a figure that is expected to reach -0.91 in the next quarter, and analysts are predicting that it will be -4.33 at the market close of one year from today.
Technical Analysis of Xenon Pharmaceuticals Inc (XENE)
Now, what If we examine the latest scores posted by [Xenon Pharmaceuticals Inc, XENE]. During the last 5-days, its volume was better the volume of 0.46 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 45.42% While, its Average True Range was 2.03.
Raw Stochastic average of Xenon Pharmaceuticals Inc (XENE) in the period of the previous 100 days is set at 30.64%, which indicates a major fall in contrast to 57.95% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 36.69% that was higher than 35.98% volatility it exhibited in the past 100-days period.
